Literature DB >> 2184877

An overview in the treatment of advanced ovarian cancer. MRC Gynaecological Cancer Working Party.

.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2184877      PMCID： PMC1971350          DOI： 10.1038/bjc.1990.111

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  6 in total

1.  Publication bias and dissemination of clinical research.

Authors:  C B Begg; J A Berlin
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

2.  Publication bias: the case for an international registry of clinical trials.

Authors:  R J Simes
Journal:  J Clin Oncol       Date:  1986-10       Impact factor: 44.544

3.  Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.

Authors:  C T Griffiths
Journal:  Natl Cancer Inst Monogr       Date:  1975-10

4.  Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.

Authors:  R C Young; B A Chabner; S P Hubbard; R I Fisher; R A Bender; T Anderson; R M Simon; G P Canellos; V T DeVita
Journal:  N Engl J Med       Date:  1978-12-07       Impact factor: 91.245

5.  Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer.

Authors:  H S Brodovsky; M Bauer; J Horton; P J Elson
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

Review 6.  Treatment decisions in advanced ovarian cancer.

Authors:  M M Cody; M L Slevin
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.